PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
TheCarCrowd is a Passion Asset Investment (PAI) platform that intends to address the lack of investment options for the 8 million UK millennials by allowing them to take a real equity stake in a classic car and benefit from the potential appreciation. The company argues that classic cars appreciated 194% over 10 years up to Q4 2019 as per expert reports. TheCarCrowd points out that its portal allows interested investors to buy shares in cars from just £20 and unlock the benefits of potential appreciation. The company asserts that its business idea has found traction amidst users with over 620 investors registering on the portal since the company's launch in November 2020. TheCarCrowd will use 12% of the investment for Public Relations (PR), 48% for marketing, and 40% for working capital.
days to go:
Expired
investment:
£379,108
Chop2Bowl is the first in a line of kitchenware products created by Lewis Pennicott Design. The core Chop2Bowl product is made up of a split-board and six bowls, which are inserted into a base unit. The split-apart function means that cross-contamination can be easily avoided.
days to go:
Expired
investment:
£33,100
Chip is one of the fastest-growing Fintech companies in the UK. Chip has built an app that uses the user's banking app to make personalised decisions about their money. Its user base has doubled since its previous fundraising in 2018. The company has 153,000 accounts, and it has processed more than £130m of savings. ChipX is the company's revolutionary returns platform and it has a waiting list of more than 50,000 people. The company is a winner of the British Bank Award, 2 Crowdcube awards, and 1 World Banking Award. It has welcomed many management executives from Funding Circle, Monzo, and Purple Bricks. Chip is now scaling with market-leading returns on ChipX. It aims to build the biggest savings account in the world. With the proceeds, the company will double its team and expand ChipX in the €10 trillion European savings market.
days to go:
Expired
investment:
£3,768,260
Byrd is a coaching platform that works around everyday life to keep people running. It asserts that its unique EQAI-coach uses 1 billion variables to coach people to their goal, whether that’s simply to remain healthy or to hit a specific event. The company estimates that 200 million people were running globally in 2018. It seeks to target this group and become a contender in a fitness market that is estimated to be worth $2.4 billion. The company has created and tested two beta versions of its Android and iOS apps. It points out that it has conducted surveys involving hundreds of runners clocking in 20,000 km of running and incorporated that data into its portal. Byrd argues that its app has been built on Google Cloud infrastructure and is ready to horizontally scale. It will use 40% of the investment in product evolution, 20% in acquisition, 23% towards marketing, and 17% towards enriching customer experience.
days to go:
Expired
investment:
£266,836
Cloud-based SaaS software with the purpose of efficiently generating corporate management reports to reduce operational costs and improve data quality. Synapse's service can be implemented into pre-existing financial reporting systems to produce automated reports, even in large companies. Customers include Lloyds Bank, who have signed a 2-year term and the Bank of England have contacted Synapse to potentially integrate the system.
days to go:
Expired
investment:
£894,056
